Please login to the form below

Not currently logged in
Email:
Password:

Less pain from needles for children

Zingo, a new drug that reduces pain caused by intravenous lines in children aged three to 18 has been launched by Californian biopharmaceutical company, Anesiva
Zingo, a new drug that reduces pain caused by intravenous (IV) lines and blood draws in children aged three to 18 has been launched by Californian biopharmaceutical company, Anesiva.

The drug is an easy-to-administer powder that works within one to three minutes to relieve pain at the site of needle insertion. Currently, anaesthetic creams can take between 30 and 60 minutes to work. The need for timesaving means this application is often sacrificed at the cost of pain to the patient.

"Zingo is the first easy-to-administer, fast-acting local anaesthetic that could lead to a paradigm shift in the approach to venous access procedures such as drawing blood and placing IV lines in children," said Dr William T Zempsky who led the paediatric trials of Zingo.

Anesiva estimates that about 18 million procedures involving IV lines or blood draws are carried out on children in US hospitals each year. Many of these patients receive ongoing and multiple procedures. Zingo will offer a significant improvement in comfort for these patients.

The US Food and Drug Administration (FDA) is reviewing a supplemental New Drug Application (sNDA) to expand Zingo's indicated use to include adults. FDA action is expected by January 2009.

30th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics